Implementation of CRP Point of Care Testing in Primary Care to Improve Antibiotic Targeting in Respiratory Illness (ICAT) — ICAT  

Acute Respiratory Infection Clinical Trial

Official title: Implementation of CRP Point of Care Testing in Primary Care to Improve Antibiotic Targeting in Respiratory Illness (ICAT)

Status Completed

Clinical Trial Summary

The proposed study will monitor and evaluate a quality improvement project - the introduction of commercially available lateral flow CRP tests with international regulatory approval, as a routine care service to improve the management of patients with acute respiratory infection (ARI) and reduce unnecessary antibiotic prescribing. No research staff will be present, and to minimise disruption and alteration of routine care, a waiver of written patient informed consent will be requested from the relevant ethical review boards, in accordance with the 2016 WHO/CIOMS International Guidance for Health-related Research Involving Humans8. Instead, patients in intervention clusters will be provided with information concerning how the test can assist healthcare workers in identifying when antibiotics are required, after which they will be free to refuse its use.

The test selected for use in the study is the Actim® CRP test from Medix Biochemica (Finland; ISO certification ISO13485:2016). The test is a simple lateral flow device that uses capillary blood, obtained through a finger/heel puncture. The test provides a semi-quantitative indication of whether CRP concentrations are <10mg/L, between 10-40mg/L, between 40-80mg/L, or above 80mg/L, in under 5 minutes with minimal training requirements. The test has been approved by the European regulatory body (CE-marking) as well as in 13 other countries around the world (including Switzerland, Norway, Iceland, Israel and Thailand) and has been validated for accuracy in previous publications.9,10 Our own research group has also confirmed the tests' accuracy in both laboratory and field environments, including their thermos-stability in a tropical climate (see annex). Neither Medix Biochemica nor any of its distributors, have had involvement with the design of the evaluation and our group has no conflict of interest with respect to the choice of the test.

Main research question: Can point of care CRP tests introduced in routine primary healthcare reduce prescription of antibiotics for patients with acute respiratory infections, outside of the research context?

Brief description of the intervention: The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam (CHC details are described in the Location section below). Prior to introduction of the tests, an educational session will be provided for local healthcare workers in both intervention and control arms about the role of antibiotics and AMR. After randomization, further training will be provided for healthcare workers in the intervention CHCs as to the use of CRP testing to guide antibiotic prescribing decisions. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI (detailed in section 5.4). Educational materials will also be developed for patients and care-givers regarding the value of CRP testing.

Description of the population to be studied: This study will be conducted in the general population of Nam Dinh, a rural province in northern Vietnam. The test will be provided at CHCs and recommended for use in patients presenting with a chief complaint of ARI.

Clinical Trial Description

STUDY PROCEDURES

1. Screening and Recruitment - A list of potential CHCs will be compiled by province-level officials, and those meeting eligibility criteria will be invited to take part. CHCs will be randomly allocated to intervention or routine care arms using a computer-generated random allocation procedure.

If baseline variability in antibiotic prescribing practices is identified from reviewing retrospective routine records, high and low prescription centres will be stratified.

In the intervention CHCs, patients with ARIs will be provided leaflets with information about CRP testing, antibiotics and AMR. Healthcare workers will then decide whether to use a CRP test as part of routine care of patients with ARI. Patients' autonomy will be respected and as with any medical procedure this test can be declined. In the control CHCs patients will be provided with an information leaflet regarding the need for rational use of antibiotics in ARIs but with no mention of CRP testing.

2. Clinical assessment - All patients will have a medical history taken and will be examined as per normal practice. In the control arm, local guidelines and WHO IMCI recommendations will guide treatment. In the intervention arm, doctors can choose to use CRP test results in addition to existing guidelines.

3. General training and education - Healthcare worker training - Before the study sites (CHCs) are randomized, an overview of the study will be presented to all local healthcare workers and provide education about the role of antibiotics, antimicrobial resistance and identification of clinical signs of severity as well as good clinical practice (GCP) for research.

Patient education - Educational materials will be developed for patients and care-givers regarding antibiotic use and AMR. These will be available to patients presenting with ARIs in both arms, with additional information regarding the CRP tests added to the intervention group leaflets.

4. Intervention - CRP test - The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.

Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.

As the purpose of the study is to establish whether antibiotic prescription rates can be reduced by using CRP POC test results, the healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs below are recommended in the absence of warning signs of severity:

CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10mg/L to 40 mg/L:

antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended. Based on the previous clinical trial of CRP testing in ARI in Vietnam in similar CHCs, it's anticipated approximately 75% of patients to have CRP levels below 10mg/L, 20% between 10-40mg/L and 5% above 40 mg/L6.

Healthcare worker training - Additional training will be provided to healthcare workers in the intervention arm. Findings from previous CRP studies have been used to inform the training and guidance for the healthcare workers.

Face-to-face training will be provided on how the test could be used to inform their prescribing behaviour and a practical session on CRP testing. Content will include which patients should be offered CRP tests; CRP cut-off values; safety nets and caution in result interpretation (including danger signs from IMCI13 and IMAI14 guidelines and patients with co-morbidities). Healthcare workers will be advised that the CRP cut offs are guidelines and that antibiotics can be prescribed or withheld according to their clinical judgement. If the healthcare worker feels the patient requires referral to a higher level facility this should be done without delay and that the CRP tests should not be used in these cases. The training will be provided by the study team in the local language.

The CHCs and healthcare workers will be given a telephone number to contact should any queries arise during the study. Laminated posters and desk reminders with the CRP cut-off values will be given to the intervention sites.In addition to general information about rational antibiotic use contained in the patient leaflet, patients in the intervention arm will have an extra section explaining the role of CRP testing to guide antibiotic prescriptions.

Patient education - Patients with ARIs in all CHCs will be provided with an information leaflet regarding rational use of antibiotics in ARI and the implications of overuse of antibiotics for the development of AMR. An additional section for the intervention arm will explain the role of CRP testing to guide antibiotic prescriptions.

5. Clinical/laboratory/other procedures - CRP tests will be available for healthcare workers to use in ARI patients consulting at intervention CHCs. If patient agree to take the test, a finger prick blood sample will be taken by the CHC staff and placed on a semi-quantitative lateral flow CRP test-kit (Actim® CRP, Medix Biochemica, Finland). Results will be available within 5-10 minutes. Other than the finger prick sample for the CRP test no samples will be taken or stored. CRP test kits and other consumables will be re-stocked on a monthly basis provided and checked to confirm they are properly used for study the study purposes only.

6. Withdrawal of participants from the study - Healthcare workers will be free to refrain from using the tests and they are not obliged to follow the guidelines in their antibiotic prescribing. Healthcare workers will also be free to decline the interviews on the usability and acceptability of the tests. Patients' autonomy will be respected and they will be free to decline the CRP test.

7. Minimization of Error and Bias - To reduce bias within healthcare providers, cluster randomisation will be used so that the same doctors will not see patients in both the intervention and control groups. The study will be conducted for 1 year to allow for seasonal variation. To measure outcomes, electronic patient record data captured routinely in health station log books will be used. This information is a requirement for national health insurance reimbursements, and will be captured in the same way in each arm. Health-workers in both arms will receive data quality training at the start of the study period.

8. Serious adverse events monitoring - As the research poses no more than minimal risks to participants, a data and safety monitory board (DSMB) will not be required. Based on previous studies it's anticipated that no serious adverse events associated with the CRP tests and patients will not be followed up. However, data on admissions for ARI at hospitals serving this catchment population will be retrospectively requested. Health insurance numbers will be used to link with primary healthcare records, in order to identify any study patients who were subsequently hospitalised. This will be done at the end of the study. ;

Related Conditions & MeSH terms

• Acute Respiratory Infection
• Respiratory Tract Infections

• NCT number: NCT03855215
• Study type: Interventional
• Source: Oxford University Clinical Research Unit, Vietnam
• Status: Completed
• Phase: N/A
• Start date: June 1, 2020
• Completion date: June 1, 2021